Boundless Bio, Pushing Frontiers with ecDNA Cancer Therapy, Raises $105M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Boundless Bio Gets $100M to Fight Cancer, NewLimit Gets $40M to Defy Aging
Orna Therapeutics, a Circular RNA Bet, Raises $80M to Overcome Classic RNA Challenges
Backed by 5AM, Ensoma Gets $70m to Make More Accessible Cell Therapies